Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.

Pharmacological research - 1 Sept 2018

Yorifuji Kennosuke, Uemura Yuko, Horibata Shinji, Tsuji Goh, Suzuki Yoko, Miyagawa Kazuya, Nakayama Kazuhiko, Hirata Ken-Ichi, Kumagai Shunichi, Emoto Noriaki

Abstract excerpt

Bosentan, an endothelin receptor antagonist, has been widely used as a first-line drug for the treatment of pulmonary arterial hypertension (PAH). In addition, bosentan is approved for patients with digital ulcers related to systemic sclerosis. Liver dysfunction is a major adverse effect of bosentan and may lead to discontinuation of therapy. The purpose of this study was to identify genomic biomarkers to predict...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antihypertensive Agents

Share to Asian People

Share to Hypertension, Pulmonary

Share to Sulfotransferases

Share to Young Adult

Source

Identifiers

PMID: 30118797
DOI: 10.1016/j.phrs.2018.08.011

Genes

PAH
CHST13
CHST3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.PMID 30118797Read ↗

Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.Semantic proximity Read ↗

Machine Learning to Identify Interaction of Single-Nucleotide Polymorphisms as a Risk Factor for Chronic Drug-Induced Liver Injury.Semantic proximity Read ↗

Association of CYP2C9*2 with bosentan-induced liver injury.Semantic proximity Read ↗

Identification of biomarkers related to copper metabolism in patients with pulmonary arterial hypertensionSemantic proximity Read ↗

Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes.Semantic proximity Read ↗

A genome-wide association study identifies a novel association between SDC3 and apparent treatment-resistant hypertension.Semantic proximity Read ↗

Novel Liver Injury Phenotypes and Outcomes in Pulmonary Arterial HypertensionSemantic proximity Read ↗

Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.Semantic proximity Read ↗

Genetic Polymorphisms Associated with Cyclophosphamide Outcome and Risk of Toxicity in Patients with Lupus Nephritis.Semantic proximity Read ↗

Research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen.Semantic proximity Read ↗

Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.